Trial Profile
A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary) ; Sargramostim (Primary)
- Indications Acute hypoxia; COVID 2019 infections; Hypoxaemia; Respiratory insufficiency
- Focus Therapeutic Use
- Acronyms SARPAC
- 01 Mar 2021 Status changed from active, no longer recruiting to completed.
- 26 Feb 2021 According to a Partner Therapeutics Media Release, the full study and translational results are being prepared for publication.
- 26 Feb 2021 Results published in the Partner Therapeutics Media Release.